Xenon Pharmaceuticals (XENE) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Pipeline and clinical milestones

• NDA for azetukalner in focal seizures filed in September; expected broad label could support an initial focus on refractory patients, with expansion toward earlier-line use over time.

• Phase IIIb/IV X-FIRST study will assess first-add-on use; enrollment is targeted for H1 2027, and the open-label study is intended to inform earlier-line activity, not necessarily expand the label.

• At AES in December 2026, plans include 60-month X-TOLE open-label extension data; just under half of enrolled patients remained on study at 48 months last year, and X-TOLE2 was published in JAMA Neurology.

• MDD and bipolar depression enrollment was paused after neuropsychiatric adverse events seen in epilepsy studies appeared in Phase III, though not in the earlier Phase IIb depression study.

• X-NOVA2 enrollment was capped at 360; topline timing moved from Q1 2027 to December 2026. Results will inform the development path and potential dose-escalation changes; HAM-D17 is the primary endpoint.

Commercial launch strategy

• Launch is expected at the beginning of 2028, following FDA review and DEA scheduling; DEA scheduling was projected for Q4 2027, with the process often taking three months.

• Initial targeting is expected to cover 5,000–6,000 physicians, including epileptologists, high-prescribing general neurologists and advanced practice providers; broader general-neurology adoption is a longer-term goal.

• Azetukalner is expected to offer four doses, no titration and no drug interactions requiring adjustment of concomitant anti-seizure medicines; dose choice can be tailored to patient needs.

• A specialty-pharmacy model is intended to support prior authorizations, copay assistance, prescription fulfillment and visibility into the patient journey, helping address abandonment in retail channels.

• Payer mix was estimated at ~40% commercial, ~40% Medicaid and the balance Medicare; epilepsy’s protected-class status supports government-program engagement, while access work and pricing strategy remain launch priorities.

Pain programs

• Three pain programs are in clinical development: two targeting NaV1.7 and one targeting KV7; Phase II proof-of-concept studies for NaV1.7 and KV7 are planned for H1 2027, initially in acute pain.

• NaV1.7 Phase I data showed target engagement in central and peripheral nervous systems, good free fraction and no autonomic nervous system effects seen with prior approaches.

• Healthy-volunteer data for the KV7 program also showed receptor occupancy, target engagement and a favorable safety profile; preclinical primate evoked-pain models showed 100% pain reduction for both NaV1.7 and KV7 assets.

• Chronic pain is viewed as the larger opportunity; potential development paths include monotherapy or combinations of NaV1.7, KV7 and NaV1.8-targeting agents.